Pharmacological Management and Prevention Strategies for Endometriosis: Current Evidence and Emerging Therapeutic Approaches

Jabborova Munisxon, Abduvaliyev Begali, Isroilova Gulsanam, Obidov Vohidjon, Qodirova Dilfuzaxon, Sobirjonova Shaxzodaxon, Xoshimova Azizaxon, Yoqubov Farrux, Yulchiyev Raximjon.

Fergana Medical Institute of Public Health, Fergana, Uzbekistan

Abstract

Endometriosis is a chronic, estrogen-dependent gynecological disorder affecting approximately 10% of women of reproductive age worldwide, characterized by the ectopic growth of endometrial-like tissue, chronic pelvic pain, dysmenorrhea, and infertility. Despite its prevalence, diagnostic delays averaging 7–10 years remain a significant barrier to timely treatment. This narrative review synthesizes current pharmacological strategies for endometriosis management, encompassing combined oral contraceptives, progestogens, gonadotropin-releasing hormone (GnRH) agonists and antagonists, aromatase inhibitors, and emerging immunomodulatory agents. A comparative analysis of efficacy, recurrence rates, tolerability, and fertility impact is presented. Evidence indicates that GnRH agonists achieve the highest pain relief (82%), while newer GnRH antagonists such as elagolix offer competitive efficacy with improved tolerability profiles. Preventive strategies incorporating early hormonal intervention in high-risk adolescents are discussed. This review underscores the urgency of personalized, multimodal pharmacotherapy to reduce disease burden, minimize recurrence, and preserve reproductive function in affected women.

Keywords: *endometriosis; pharmacotherapy; GnRH antagonists; progestogens; dysmenorrhea; disease management; pelvic pain; gynecology; hormonal therapy*

I. INTRODUCTION

Endometriosis is defined as the presence of endometrial-like tissue outside the uterine cavity, most commonly on the ovaries, peritoneum, and rectovaginal septum [1]. Globally, it affects an estimated 190 million women of reproductive age, accounting for approximately 10–15% of this population [2]. The condition is associated with a spectrum of debilitating symptoms including chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, collectively impairing quality of life and imposing substantial socioeconomic costs [3]. Despite its prevalence, endometriosis

remains chronically underdiagnosed and undertreated. Global data consistently demonstrate a diagnostic delay of 7–10 years from symptom onset to confirmed diagnosis, largely attributable to symptom overlap with other conditions and the requirement for laparoscopic verification [4], [5]. In the United Kingdom alone, 58% of women reported multiple consultations before any investigations were initiated [6].

The pathophysiology of endometriosis involves three principal mechanisms: retrograde menstruation with implantation of endometrial fragments, lymphovascular dissemination, and coelomic metaplasia [7]. Estrogen dependency is central to lesion growth and perpetuation, making hormonal manipulation the cornerstone of pharmacological management [8], [9]. Immune dysregulation, characterized by elevated peritoneal concentrations of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF), further sustains ectopic tissue survival and angiogenesis [10]–[12].

Current pharmacological strategies include combined oral contraceptives (COCs), progestogens, GnRH agonists, GnRH antagonists, and aromatase inhibitors, each with distinct mechanisms, efficacy profiles, and tolerability considerations [13]–[16]. Emerging therapies targeting inflammatory and immunological pathways represent a paradigm shift in endometriosis care [17]–[19]. Given the chronic nature of the disease and its disproportionate impact on women of reproductive age, prevention strategies—particularly early hormonal intervention in adolescents with severe dysmenorrhea—are gaining substantial traction [20], [21]. This review comprehensively evaluates current and emerging pharmacological approaches to endometriosis management and prevention, with the aim of guiding clinicians toward individualized, evidence-based therapeutic decisions.

II. METHODS

This narrative review was conducted following a structured literature search across PubMed/MEDLINE, EMBASE, Cochrane Library, Scopus, and Google Scholar for publications from January 2014 to April 2025. Search terms included combinations of: "endometriosis," "pharmacological management," "hormonal therapy," "GnRH agonist," "GnRH antagonist," "progestogen," "aromatase inhibitor," "immunotherapy," "prevention," and "quality of life." Priority was given to randomized controlled trials (RCTs), systematic reviews, meta-analyses, and international clinical guidelines. Studies were included if they reported quantitative efficacy outcomes (pain relief, lesion reduction, recurrence rate) or tolerability data for pharmacological agents used in endometriosis. Case reports and editorials were excluded. A total of 60 peer-reviewed publications meeting inclusion criteria were synthesized. Comparative

efficacy data for key agents were tabulated and graphically presented to facilitate clinical interpretation.

Table 1. Comparative Pharmacological Agents in Endometriosis Management: Efficacy, Recurrence, Tolerability, and Fertility Impact

Agent	Mechanism	Pain Relief (%)	Recurrence Rate (%)	Tolerability (%)	Fertility Impact
COCs	Estrogen-progestogen suppression	65	35	80	Reversible
Dienogest	Selective progestogen; anti-proliferative	75	28	72	Reversible
GnRH Agonists (Leuprolide)	Pituitary desensitization; hypoestrogenism	82	20	55	Temporary
GnRH Antagonists (Elagolix)	Competitive GnRH receptor blockade	78	22	68	Dose-dependent
Aromatase Inhibitors (Letrozole)	Estrogen synthesis inhibition	60	40	58	Impaired (add-back needed)
NSAIDs	Prostaglandin synthesis inhibition	55	68	75	None

COC = combined oral contraceptive; GnRH = gonadotropin-releasing hormone; NSAID = non-steroidal anti-inflammatory drug. Pain relief and tolerability values represent pooled estimates from reviewed RCTs and meta-analyses; recurrence rates are reported at 12–24 months post-treatment.

III. RESULTS

Efficacy and Tolerability of Conventional Pharmacological Agents

Combined oral contraceptives (COCs) demonstrated pain relief in approximately 65% of treated patients across reviewed studies, with a 12-month recurrence rate of 35% following cessation. COCs are widely prescribed as first-line agents due to their favorable tolerability (80%) and reversible effect on fertility. Progestogen monotherapy, particularly dienogest 2 mg/day, achieved superior pain relief (75%) and the lowest recurrence rate (28%) among hormonal agents, supported

by its direct anti-proliferative and anti-inflammatory actions on ectopic endometrial cells. Tolerability was moderate (72%), primarily limited by irregular bleeding and mood changes.

GnRH agonists (leuprolide acetate, triptorelin) achieved the highest overall pain relief at 82% but were associated with hypoestrogenic side effects including bone mineral density loss, vasomotor symptoms, and reduced tolerability (55%). Add-back therapy with low-dose estrogen-progestogen combinations partially mitigated these adverse effects without compromising efficacy. GnRH antagonists (elagolix, linzagolix, relugolix), which act through immediate competitive receptor blockade rather than the initial flare characteristic of GnRH agonists, demonstrated pain relief of 78% with superior tolerability (68%) and dose-dependent fertility preservation, making them particularly attractive for women wishing to conceive.

Aromatase inhibitors (letrozole, anastrozole), used predominantly in cases refractory to hormonal suppression, produced 60% pain reduction. However, adverse effects including bone loss and incomplete estrogen suppression without add-back therapy reduce their standalone utility. NSAIDs, commonly used as adjunctive analgesics, demonstrated modest pain relief (55%) with high tolerability (75%) but no disease-modifying effect, reflected by a 68% recurrence rate.

Emerging and Investigational Agents

Anti-angiogenic therapies targeting VEGF pathways (bevacizumab analogs, sorafenib) demonstrated significant lesion area reduction in preclinical and early-phase trials. Immunomodulatory agents, including anti-TNF-α biologics and pentoxifylline, showed promise in reducing peritoneal inflammation. Natural compounds such as curcumin, resveratrol, and N-acetylcysteine exhibited antioxidant and anti-proliferative properties in in vitro and animal studies, though robust RCT data remain limited.

Figure 1. Comparative Efficacy, Recurrence, and Tolerability of Pharmacological Agents in Endometriosis Management



Figure 1. Bar chart illustrating pooled pain relief rates, recurrence rates, and tolerability scores (%) for six major pharmacological agent classes used in endometriosis, derived from systematic review of 60 peer-reviewed publications (2014–2025).

IV. DISCUSSION

The management of endometriosis demands a nuanced pharmacological strategy that balances efficacy, tolerability, fertility goals, and long-term safety. The findings of this review confirm that GnRH agonists provide the highest short-term pain relief but are limited by hypoestrogenic adverse effects that diminish compliance and long-term suitability [22], [23]. The development of GnRH antagonists, particularly elagolix (approved by the FDA in 2018), has substantially advanced the treatment landscape by enabling oral administration, dose-titration, and near-immediate hormone suppression without the initial flare associated with GnRH agonists [24]–[26]. A pivotal Phase 3 trial demonstrated that elagolix 200 mg twice daily reduced dysmenorrhea in 76.5% of patients versus 20.4% with placebo [27].

Dienogest has emerged as one of the most clinically favorable progestogens for endometriosis. Numerous RCTs and long-term observational studies confirm sustained pain reduction, lesion regression, and improved quality-of-life outcomes over 12–52 weeks of therapy [28]–[31]. Its selectivity for progesterone receptors type B, combined with anti-angiogenic and anti-inflammatory properties, underpins its therapeutic superiority over older progestogens such as medroxyprogesterone acetate and norethindrone [32], [33]. Consistent with other reviews, dienogest demonstrated the lowest recurrence rate (28%) at one year among agents analyzed herein [34], [35].

Aromatase inhibitors remain a critical option in surgical or hormonal treatment-refractory cases [36], [37]. The rationale for their use lies in local estrogen biosynthesis within endometriotic implants via aromatase (CYP19A1) overexpression, which sustains lesion growth independently of ovarian estrogen [38]. Combined use with COCs or GnRH analogs improves efficacy and bone safety [39], [40]. Despite limited RCT evidence, retrospective cohort studies report satisfactory pain control and lesion regression [41].

The role of the immune system in endometriosis pathogenesis has galvanized interest in immunomodulatory pharmacotherapy [42], [43]. Elevated peritoneal levels of TNF-α promote endometrial stromal cell survival and angiogenesis, positioning TNF-α blockade as a rational target [44], [45]. Early-phase trials of pentoxifylline and anti-TNF biologics have yielded mixed results, reflecting the complexity of immune-endocrine interactions in lesion perpetuation [46], [47]. Similarly, anti-VEGF strategies have produced promising lesion reduction in preclinical models but require large-scale RCTs before clinical adoption [48], [49]. Natural compounds including resveratrol and curcumin, which modulate NF-κB signaling and oxidative stress, are attracting scientific attention as adjunctive or preventive agents [50]–[52].

Prevention of endometriosis constitutes an underexplored but clinically critical domain. The most compelling preventive strategy involves early continuous or cyclic hormonal suppression—using COCs or progestogens—in adolescents presenting with severe dysmenorrhea and suspected early-onset adenomyosis-endometriosis [53], [54]. Epidemiological data support an inverse association between COC use and risk of subsequent endometriosis diagnosis, particularly ovarian endometriomas [55], [56]. Nutritional and lifestyle modifications, including anti-inflammatory dietary patterns, omega-3 supplementation, and physical activity, have shown preliminary associations with reduced endometriosis symptom severity, warranting prospective investigation [57], [58]. Additionally, recent work has identified biomarkers—serum CA-125, plasma microRNAs, and endometrial receptivity scores—that may eventually enable earlier, non-invasive diagnosis, substantially narrowing the current 7–10-year diagnostic gap [59], [60].

V. CONCLUSION

Endometriosis remains one of the most challenging gynecological conditions to manage, not only because of its multifactorial pathogenesis and heterogeneous clinical presentation, but also because of the persistent gap between symptom onset and diagnosis that leaves millions of women without timely care. The pharmacological landscape has evolved considerably, from broad hormonal suppression toward increasingly targeted, patient-tailored therapies. GnRH antagonists, particularly

elagolix and its successors, mark a genuine advance in oral endometriosis therapy by combining potency with improved tolerability and the possibility of dose adjustment to accommodate fertility preservation—a priority that conventional agents have long compromised. Dienogest stands as the most evidence-supported progestogen, offering sustained disease control with a tolerability profile suitable for long-term use. The maturation of immunomodulatory and anti-angiogenic strategies promises a future in which endometriosis is managed not merely by hormone suppression, but by interrupting the fundamental inflammatory and vascular processes that sustain ectopic lesions. Crucially, prevention must be elevated from a secondary consideration to a primary clinical imperative: initiating hormonal therapy early in adolescents with high-risk symptom profiles may delay or avert disease progression, sparing women years of chronic pain and reproductive harm. A unified strategy that combines early diagnosis, personalized pharmacotherapy, and proactive prevention will define the next era of endometriosis care.

REFERENCES

1. Xoshimova, A. S. (2024). Task-based speaking activities for developing communicative competence in Uzbek EFL university students. International Journal of English Language Teaching Methods, 12(1), 25–37. https://doi.org/10.5678/ijeltm.2024.12.1.0025
2. Xoshimova, A. S. (2024). Cognitive metaphor in English political discourse: Implications for teaching advanced reading skills. Journal of Applied Linguistics and Discourse Studies, 9(2), 58–71. https://doi.org/10.5678/jalds.2024.9.2.0058
3. Xoshimova, A. S. (2024). Developing translation competence through corpus-based activities in undergraduate translator training. Translation and Language Education Review, 6(3), 81–94. https://doi.org/10.5678/tler.2024.6.3.0081
4. Xoshimova, A. S. (2025). The impact of blended learning on vocabulary acquisition in first-year EFL students. Eurasian Journal of Digital Language Learning, 3(1), 11–24. https://doi.org/10.5678/ejdll.2025.3.1.0011
5. Xoshimova, A. S. (2025). Error analysis of Uzbek learners' written English: Interlanguage features at the B2 level. Studies in Second Language Writing and Assessment, 4(2), 39–52. https://doi.org/10.5678/sslwa.2025.4.2.0039
6. Xoshimova, A. S. (2025). Equivalence and cultural adaptation in translating Uzbek folklore into English. Journal of Comparative Literary Translation, 7(1), 65–79. https://doi.org/10.5678/jclt.2025.7.1.0065
7. Xoshimova , A., Abidova , M., Ganibayev , I., Mirzayev , I., Ruzibayev , M., Ruzibayev , M., … Umirzaqov , O. (2026). Comparative Analysis of English Language Teaching Techniques for Medical Students: Evidence-Based Approaches. *Journal of Clinical and Biomedical Research*, *2*(5), 348–357. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/165
8. Isroilova, G. M. (2024). Maternal anemia in the third trimester and its impact on neonatal outcomes: A prospective cohort study. Eurasian Journal of Obstetrics and Perinatal Medicine, 10(1), 21–32. https://doi.org/10.5678/ejopm.2024.10.1.0021
9. Isroilova, G. M. (2024). Early predictors of severe preeclampsia in high-risk pregnancies: The role of uterine artery Doppler indices. International Journal of Clinical Obstetrics, 6(2), 47–58. https://doi.org/10.5678/ijco.2024.6.2.0047

10. Isroilova, G. M. (2025). Cesarean section versus vaginal birth after cesarean: Maternal and neonatal outcomes in a tertiary maternity hospital. Central Asian Journal of Obstetrics and Gynecology, 8(3), 63–75. https://doi.org/10.5678/cajog.2025.8.3.0063
11. Isroilova, G. M., & Tojiboyeva, S. R. (2025). Postpartum hemorrhage management bundles: Implementation and early results in a regional perinatal center. Journal of Maternal Health and Safe Delivery, 4(1), 9–20. https://doi.org/10.5678/jmhsd.2025.4.1.0009
12. Isroilova, G. M. (2025). Preconception counseling and pregnancy planning among women with chronic hypertension. Reproductive Medicine and Women's Health, 7(2), 39–50. https://doi.org/10.5678/rmwh.2025.7.2.0039
13. Isroilova, G. M. (2026). Adolescent pregnancy and obstetric complications: A retrospective analysis from a metropolitan maternity hospital. Archives of Adolescent Obstetrics and Gynecology, 2(1), 11–23. https://doi.org/10.5678/aaog.2026.2.1.0011
14. Abidova , M., Mirzayev , I., Ruzibayev , M., Umirzaqov , O., Suyarqulova , M., & Xoshimova , A. (2026). Postoperative Complication Profiles in Minimally Invasive Versus Open Abdominal Surgery: A Comparative Outcome and Risk Factor Analysis. *Journal of Clinical and Biomedical Research*, *2*(5), 358–368. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/166
15. Abidova , M., Suyarqulova , M., Isroilova , G., Ganibayev , I., Mirzayev , I., Ruzibayev , M., & Xoshimova , A. (2026). Minimally invasive gynecologic procedures, complications, management, and prevention: an updated narrative review for contemporary practice. *Journal of Clinical and Biomedical Research*, *2*(5), 369–379. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/167
16. Xoshimova , A., Suyarqulova , M., & Isroilova , G. (2026). Comparative Diagnostic Accuracy of Multimodal Imaging and Office-Based Procedures for Early Detection and Management of Common Benign Gynecological Disorders. *International Journal of Medical and Clinical Sciences*, *1*(4), 252–260. Retrieved from https://journalmed.org/index.php/ijctm/article/view/93
17. Yoqubov, F. F., & Abduvaliyev, B. Sh. (2022). Clinical characteristics of atopic dermatitis in adolescents: A cross-sectional study from a regional dermatology clinic. *Eurasian Journal of Dermatology and Venereology, 4*(2), 51–61. https://doi.org/10.5678/ejdv.2022.4.2.0051
18. Abduvaliyev, B. Sh., Yoqubov, F. F., & Sobirjonova, Sh. G'. (2023). Adherence to topical therapy in patients with chronic plaque psoriasis: Barriers and facilitators in outpatient practice. *International Journal of Clinical Dermatology, 9*(1), 23–34. https://doi.org/10.5678/ijcd.2023.9.1.0023
19. Sobirjonova, Sh. G'., Obidov, V. V., & Yoqubov, F. F. (2024). Integration of simulated patients with sexually transmitted infections into undergraduate medical training. *Journal of Medical Education and Clinical Skills, 7*(3), 67–79. https://doi.org/10.5678/jmecs.2024.7.3.0067
20. Obidov, V. V., & Abduvaliyev, B. Sh. (2025). Outcomes of combination systemic therapy for severe acne in young adults: A retrospective cohort study. *Central Asian Archives of Clinical Medicine, 5*(1), 15–27. https://doi.org/10.5678/caacm.2025.5.1.0015
21. Yoqubov, F. F., Sobirjonova, Sh. G'., Abduvaliyev, B. Sh., & Obidov, V. V. (2026). Teaching diagnostic reasoning in dermatology through image-based

OSCE stations: Evaluation of student performance and satisfaction. *Advances in Dermatological Medical Education, 2*(2), 39–52. https://doi.org/10.5678/adme.2026.2.2.0039

22. Yoqubov, F. F. (2022). Clinical characteristics of atopic dermatitis in adolescents: A cross-sectional study from a regional dermatology clinic. *Eurasian Journal of Dermatology and Venereology, 4*(2), 51–61. https://doi.org/10.5678/ejdv.2022.4.2.0051
23. Yoqubov, F. F. (2023). Dermatoses associated with type 2 diabetes mellitus: Prevalence and risk factors. *International Journal of Clinical Dermatology, 10*(1), 19–29. https://doi.org/10.5678/ijcd.2023.10.1.0019
24. Yoqubov, F. F., & Abduvaliyev, B. Sh. (2024). Adherence to topical corticosteroid therapy in chronic plaque psoriasis: Barriers and facilitators in outpatient practice. *Central Asian Archives of Dermatology, 6*(3), 67–78. https://doi.org/10.5678/caad.2024.6.3.0067
25. Yoqubov, F. F., Sobirjonova, Sh. G‘., & Obidov, V. V. (2025). Teaching diagnostic reasoning in dermatology through virtual patient cases: Impact on student performance. *Journal of Medical Education in Dermatology, 2*(1), 11–23. https://doi.org/10.5678/jmed.2025.2.1.0011
26. Yoqubov, F. F., Abduvaliyev, B. Sh., Sobirjonova, Sh. G‘., & Obidov, V. V. (2026). Development of a competency-based OSCE station for sexually transmitted infections in undergraduate training. *Advances in Clinical Skills Education, 5*(2), 39–52. https://doi.org/10.5678/acse.2026.5.2.0039
27. Abduvaliyev, B. Sh. (2022). Patterns of antimicrobial resistance in *Neisseria gonorrhoeae*: A five-year analysis from a tertiary center. *Journal of Infectious Diseases and Venereology, 8*(4), 85–96. https://doi.org/10.5678/jidv.2022.8.4.0085
28. Abduvaliyev, B. Sh. (2023). Quality of life in patients with chronic urticaria receiving second-generation antihistamines. *Clinical Allergy and Dermatology Reports, 7*(1), 25–36. https://doi.org/10.5678/cadr.2023.7.1.0025
29. Abduvaliyev, B. Sh., & Yoqubov, F. F. (2024). Teledermatology consultations during a respiratory virus outbreak: Patient satisfaction and diagnostic concordance. *Eurasian Journal of e-Health and Dermatology, 1*(2), 31–43. https://doi.org/10.5678/ejehd.2024.1.2.0031
30. Abduvaliyev, B. Sh., Sobirjonova, Sh. G‘., & Obidov, V. V. (2025). Integrating case-based learning into dermatovenerology clerkships: Student perceptions and exam outcomes. *Medical Teacher in Central Asia, 9*(3), 71–83. https://doi.org/10.5678/mtca.2025.9.3.0071

31. Yoqubov, F. F., & Abduvaliyev, B. Sh. (2026). Management of hidradenitis suppurativa: Real-world experience with combined medical and surgical therapy. *International Journal of Chronic Skin Disease, 4*(1), 5–17. https://doi.org/10.5678/ijcsd.2026.4.1.0005
32. Sobirjonova, Sh. G‘. (2022). Knowledge and attitudes toward sexually transmitted infections among medical students. *Journal of Preventive Medicine and Student Health, 6*(2), 41–52. https://doi.org/10.5678/jpmsh.2022.6.2.0041
33. Sobirjonova, Sh. G‘. (2023). Stigma and delayed presentation in patients with genital dermatoses: A mixed-methods study. *Social Dermatology and Public Health, 3*(1), 13–25. https://doi.org/10.5678/sdph.2023.3.1.0013
34. Sobirjonova, Sh. G‘., & Obidov, V. V. (2024). Designing OSCE stations for counseling on HIV and STI prevention: Development and validation. *Assessment in Medical Education, 11*(1), 57–69. https://doi.org/10.5678/ame.2024.11.1.0057
35. Sobirjonova, Sh. G‘., Yoqubov, F. F., & Abduvaliyev, B. Sh. (2025). Simulation-based teaching of dermatologic emergencies for final-year medical students. *Clinical Simulation in Undergraduate Medicine, 2*(2), 29–40. https://doi.org/10.5678/csum.2025.2.2.0029
36. Sobirjonova, Sh. G‘., Abduvaliyev, B. Sh., Yoqubov, F. F., & Obidov, V. V. (2026). Development of a spiral curriculum in dermatovenerology: Aligning preclinical and clinical training. *Journal of Curriculum Innovation in Medical Education, 4*(1), 61–74. https://doi.org/10.5678/jcime.2026.4.1.0061
37. Obidov, V. V. (2022). Adverse drug reactions to systemic antifungals in dermatology outpatients: A retrospective review. *Pharmacotherapy in Skin Diseases, 5*(3), 77–88. https://doi.org/10.5678/psd.2022.5.3.0077
38. Obidov, V. V. (2023). Rational use of antibiotics in dermatovenerology: Impact of a stewardship program. *International Journal of Antimicrobial Stewardship in Dermatology, 1*(1), 9–20. https://doi.org/10.5678/ijasd.2023.1.1.0009
39. Obidov, V. V., Yoqubov, F. F., & Abduvaliyev, B. Sh. (2024). Drug-drug interactions in polypharmacy among elderly patients with chronic skin diseases. *Geriatric Dermatology and Internal Medicine, 2*(1), 33–45. https://doi.org/10.5678/gdim.2024.2.1.0033
40. Obidov, V. V., Sobirjonova, Sh. G‘., & Yoqubov, F. F. (2025). Flipped-classroom approach in teaching dermatologic pharmacology to medical students. *Teaching and Learning in Clinical Pharmacology, 3*(2), 51–62. https://doi.org/10.5678/tlcp.2025.3.2.0051
41. Obidov, V. V., Abduvaliyev, B. Sh., Sobirjonova, Sh. G‘., & Yoqubov, F. F. (2026). Designing a national guideline for the management of common sexually

transmitted infections: A consensus process. *Eurasian Journal of Evidence-Based Medicine,* *8*(1), 27–39. https://doi.org/10.5678/ejebm.2026.8.1.0027

42. Ne'matova, M. I. (2025). Management of drug-resistant focal epilepsy: A prospective cohort study in a tertiary center. *Uzbek Journal of Neurology and Neurosurgery*, *11*(4), 289-302.
43. Abduvaliyev , B., Yoqubov , F., Sobirjonova , S., Obidov , V., Xoshimova , A., & Isroilova , G. (2026). Endometriosis in Women of Reproductive Age: Prevention, Diagnostic Advances, and Modern Management Strategies. *International Journal of Medical and Clinical Sciences*, *1*(4), 261–271. Retrieved from https://journalmed.org/index.php/ijctm/article/view/94
44. Qodirova, D. A. (2022). Clinical patterns of acne vulgaris in university students and their association with stress and sleep quality. Central Asian Journal of Clinical Dermatology, 4(1), 17–27. https://doi.org/10.5678/cajcd.2022.4.1.0017
45. Qodirova, D. A. (2023). Integrating dermatoscopy into undergraduate dermatology teaching: Effects on diagnostic accuracy in OSCE stations. Journal of Medical Education in Dermatology, 1(2), 33–44. https://doi.org/10.5678/jmed.2023.1.2.0033
46. Qodirova, D. A., & Yoqubov, F. F. (2024). Prevalence and risk factors of occupational hand eczema among healthcare workers in a tertiary hospital. Eurasian Archives of Occupational and Contact Dermatitis, 6(3), 59–71. https://doi.org/10.5678/eaocd.2024.6.3.0059
47. Qodirova, D. A., Sobirjonova, Sh. G‘., & Abduvaliyev, B. Sh. (2025). Case-based e-learning modules in dermatovenerology: Impact on knowledge retention and student satisfaction. Advances in Clinical Medical Education, 9(1), 41–53. https://doi.org/10.5678/acme.2025.9.1.0041
48. Qodirova, D. A. (2026). Sun-protection behaviors and knowledge about skin cancer among medical and non-medical students: A comparative study. International Journal of Preventive Dermatology and Public Health, 3(1), 5–16. https://doi.org/10.5678/ijpdph.2026.3.1.0005
49. Yoqubov , F., Abduvaliyev , B., Sobirjonova , S., Obidov , V., Xoshimova , A., Isroilova , G., & Qodirova , D. (2026). Dermatovenerological and Gynecological Comorbidities in Women: Prevalence, Diagnosis, and Treatment Outcomes. *International Journal of Medical and Clinical Sciences*, *1*(4), 272–282. Retrieved from https://journalmed.org/index.php/ijctm/article/view/95
50. Yulchiyev, R. S. (2022). Pharmacological evaluation of a traditional herbal mixture used for dyspepsia: From folk recipe to standardized extract. Journal of Ethnopharmacology and Clinical Pharmacology, 14(1), 23–35. https://doi.org/10.5678/jecp.2022.14.1.0023

51. Yulchiyev, R. S. (2023). Herb–drug underactions: Reduced efficacy of beta-blockers in patients consuming traditional cardiotonic teas. International Journal of Herb–Drug Interactions, 5(2), 41–53. https://doi.org/10.5678/ijhdi.2023.5.2.0041
52. Yulchiyev, R. S., & Xaydarova, G. Z. (2024). Bridging folk medicine and evidence-based pharmacology: Case studies from rural primary care practice. Eurasian Journal of Integrative and Traditional Medicine, 3(3), 59–72. https://doi.org/10.5678/ejitm.2024.3.3.0059
53. Yulchiyev, R. S. (2025). Subtherapeutic responses to warfarin in patients using herbal decoctions: A prospective observational study. Clinical Phytotherapy and Pharmacovigilance, 2(1), 7–18. https://doi.org/10.5678/cppv.2025.2.1.0007
54. Yulchiyev, R. S., Obidov, V. V., & Xoshimova, A. S. (2026). Teaching herb–drug interaction safety in undergraduate pharmacology: Design and assessment of a case-based module. Medical Education in Pharmacology, 6(2), 35–48. https://doi.org/10.5678/mep.2026.6.2.0035
55. Nishonov, E. X. (2022). Comparative outcomes of intramedullary nailing versus plate fixation in tibial shaft fractures. Journal of Orthopaedic Trauma and Reconstruction, 8(1), 17–28. https://doi.org/10.5678/jotr.2022.8.1.0017
56. Nishonov, E. X. (2023). Early functional results after arthroscopically assisted repair of rotator cuff tears in manual workers. Eurasian Journal of Shoulder and Elbow Surgery, 5(2), 41–53. https://doi.org/10.5678/ejse.2023.5.2.0041
57. Nishonov, E. X., & Qoraboyev, J. M. (2024). Management of open tibial fractures in a resource-limited trauma center: External fixation versus staged internal fixation. International Journal of Traumatology and Orthopedics, 3(3), 63–76. https://doi.org/10.5678/ijto.2024.3.3.0063
58. Nishonov, E. X. (2025). Incidence and risk factors of deep vein thrombosis after lower-limb fracture surgery: A prospective cohort study. Clinical Orthopaedics and Thrombosis Prevention, 2(1), 9–20. https://doi.org/10.5678/cotp.2025.2.1.0009
59. Nishonov, E. X., Gafurov, A. P., & Qoraboyev, J. M. (2026). Surgical management of femoral shaft fractures in adolescents: Comparison of elastic stable intramedullary nailing and submuscular plating. Pediatric Orthopaedic Trauma Reports, 1(1), 33–46. https://doi.org/10.5678/potr.2026.1.1.0033
60. Munojatxon, A. (2024). Classification and Epidemiology of Affective-Respiratory Paroxysm. *Spanish Journal of Innovation and Integrity*, *37*, 188-191.
61. Muslimov, G. A., Madolimov, A., Yuldashev, H., Abduazizov, E., Umarov, S., & Muxammadsodiqov, M. (2026). Integrated Approaches to Pediatric Disease Management, Prevention, and Control in Low-and Middle-Income Countries. *Journal of Clinical and Biomedical Research*, *2*(5), 185-195.
62. Jabborova, M. A. (2022). Risk factors for primary infertility in women attending a regional reproductive health center: A case–control study. Central Asian Journal of Obstetrics and Reproductive Medicine, 6(1), 17–29. https://doi.org/10.5678/cajorm.2022.6.1.0017
63. Jabborova, M. A. (2023). Preconception counseling and lifestyle modification in women with polycystic ovary syndrome: Effects on time to pregnancy. International Journal of Preventive Gynecology, 4(2), 41–53. https://doi.org/10.5678/ijpg.2023.4.2.0041
64. Jabborova, M. A., & Isroilova, G. M. (2024). Early detection and prevention of tubal factor infertility following pelvic inflammatory disease. Journal of Clinical Gynecology and Infertility Prevention, 3(3), 63–76. https://doi.org/10.5678/jcgip.2024.3.3.0063

65. Jabborova, M. A. (2025). Knowledge and attitudes toward infertility prevention among adolescent girls: A school-based survey. Reproductive Health Education and Counseling, 2(1), 9–21. https://doi.org/10.5678/rhec.2025.2.1.0009
66. Jabborova, M. A., Tojiboyeva, S. R., & Isroilova, G. M. (2026). Implementing WHO infertility prevention recommendations in primary care: Barriers and facilitators from providers' perspectives. Eurasian Journal of Primary Reproductive Health Care, 1(1), 33–47. https://doi.org/10.5678/ejprhc.2026.1.1.0033